<DOC>
	<DOC>NCT02724735</DOC>
	<brief_summary>All subjects completing the randomized treatment period in Protocol NS2014-1 will discontinue study drug and be asked to provide consent to be followed in this 6-month study, at their final safety visit. The study will consist of an enrollment visit, followed by bi-monthly in-clinic visits with monthly telephone visits between in-clinic visits.</brief_summary>
	<brief_title>A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder</brief_title>
	<detailed_description>Following completion of the NS2014-1 final study visit procedures, Subjects will be offered the opportunity to enroll in this longitudinal observational cohort protocol to monitor their depression and to assess durability of effect and long-term safety of NSI-189. The Enrollment Visit begins when informed consent is signed.The duration of the follow-up period will be up to 6 months, until the start of a new antidepressant treatment. Subjects who provide consent will be seen for in-person visits every 8 weeks, with bi-monthly phone visits occurring between in-person visits. Safety assessments and efficacy assessments will be performed at each visit. No study drug will be taken during the Longitudinal Observational Cohort study.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>1. Subject has the ability to understand the purpose, potential benefits and risks of the study and to provide signed and dated informed consent, authorizing the use of protected health information in accordance with national and local Subject privacy regulations. 2. Subject completed the 12week randomized treatment period and final study visit for the NS20141 clinical study. 1. Subjects taking excluded medications. 2. Subject who, in the opinion of the Site Investigator, are unable to understand the protocol requirements, instructions and studyrelated restrictions, the nature, scope and possible consequences of the clinical study. 3. Subject who, in the opinion of the Site Investigator, are unlikely to comply with the protocol requirements, instructions and studyrelated restrictions; e.g., uncooperative attitude, inability to return for followup and improbability of completing the clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder (MDD)</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Neurogenesis</keyword>
	<keyword>Synaptogenesis</keyword>
	<keyword>NSI-189</keyword>
	<keyword>Neuralstem</keyword>
</DOC>